Search
GMP Biopharmaceutical Manufacturing
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
SynCo Completes Production of AG011 for PhII Trials
Posted: 26/05/2008
SynCo Bio Partners has completed production of AG011 for ActoGenIX, enabling the latter firm to begin examining it in patients suffering from ulcerative colitis (UC).
AG011, which is also being assessed in Crohn's disease (CD), is a preparation of the food bacterium Lactococcus lactis that has been modified using ActoGenIX' TopAct technology to deliver the anti-inflammatory cytokine interleukin 10 (IL-10) to the gastrointestinal (GI) tract.
© All rights reserved 2011 SynCo Bio Partners
